Are MOTS-c supplements the same as MOTS-c peptide?

Usually, the name alone cannot establish that. A product marketed as a MOTS-c booster may contain nutrients or plant extracts and claim to support the body's own production rather than deliver intact MOTS-c. The ingredient panel should say what is actually present. No human trial has shown that a support blend raises MOTS-c or reproduces an injected-peptide result.

Does the body naturally make MOTS-c?

Yes. MOTS-c is a 16-amino-acid peptide encoded by a short stretch of mitochondrial DNA. A small human exercise study found that body-made MOTS-c changed in muscle and circulation after hard cycling. That observation helps explain the biology, but it does not show that a supplement can boost the peptide or that higher levels create a clinical benefit.

Can any peptide work as a pill?

Some can, but only with a formulation designed and tested to overcome digestion and poor absorption. Developers may use protective coatings, enzyme blockers or absorption enhancers, then measure how much intact peptide reaches circulation. MOTS-c does not have a published oral formulation with human absorption data, so success with a different peptide cannot be transferred to MOTS-c tablets.

Was oral MOTS-c ever tested in animals?

Yes, with an important limit. A 2023 mouse colitis study reported no significant improvement from oral native MOTS-c. The researchers then made a modified analogue by attaching a cell-penetrating peptide, and that new molecule showed an effect in mice. It was not ordinary MOTS-c, not a human study and not evidence for a retail tablet or capsule.

Is MOTS-c FDA-approved?

No. MOTS-c has never been an FDA-approved product, and compounded MOTS-c is not FDA-approved. In a July 2026 staff briefing, FDA also reported that it had not identified publicly available human exposure data for the peptide by any route. Regulatory status is one part of a clinical decision; a licensed provider and patient decide whether a compounded prescription is appropriate.

MOTS-c Tablets: No Human Evidence Supports Them

MOTS-c tablets are not an evidence-backed way to take MOTS-c. No published human study has shown that swallowed MOTS-c reaches the bloodstream intact, and the animal experiments behind most claims used injections. A capsule sold as a "MOTS-c supplement" may instead claim to support the MOTS-c the body already makes. That is a different product and a different claim, with no human trial showing that it raises MOTS-c or recreates an injected-peptide result.

The careful answer is not that an oral version could never be developed. It is that a tablet would need its own absorption and clinical data, and those data do not exist today.

Do MOTS-c tablets work?

There is no human evidence that they do. MOTS-c is a peptide, a short chain of amino acids. This one contains 16. When a peptide is swallowed, stomach acid and digestive enzymes can cut that chain into smaller pieces, while the gut wall makes it hard for a large intact molecule to enter the blood.

That leaves two questions for any oral peptide: does enough of it survive, and does enough cross the gut wall? Bioavailability means the share of a dose that reaches circulation intact. No published study has measured oral bioavailability for MOTS-c in people. A recent review of oral peptide delivery describes enzymatic breakdown, instability and poor movement across the gut lining as the central barriers (Baral and Choi, Pharmaceutics, 2025).

Calling a product a tablet, capsule or supplement does not answer either question. The delivery system has to be described and tested with the actual molecule.

What the MOTS-c studies actually tested

The 2015 paper that identified MOTS-c found that it is encoded in mitochondrial DNA. Mitochondria are the small structures inside cells that make most usable cellular energy. In the intervention part of that study, researchers gave MOTS-c to mice by intraperitoneal injection, meaning into the abdominal cavity in a laboratory animal (Lee et al., Cell Metabolism, 2015). They did not use pills or people.

A 2021 study also separated two very different questions. Ten healthy young men completed a hard cycling session while researchers measured the MOTS-c their bodies produced. The peptide was not given to them. The treatment experiments used injections in mice (Reynolds et al., Nature Communications, 2021). The broader MOTS-c benefits evidence is mostly cell and animal work, so route and species matter every time a result is repeated.

There is one oral animal experiment worth knowing about. In a 2023 mouse colitis study, swallowed native MOTS-c did not produce a significant improvement. Researchers then attached a cell-penetrating peptide to create a new molecule called MP; that modified analogue did show an effect in the mice. An analogue is a deliberately altered version of a molecule, not the original molecule in a capsule (Jiang et al., Eur J Pharmacol., 2023). This is a clue for drug developers, not evidence that ordinary MOTS-c pills work in people.

Why an engineered oral peptide is different

Some peptide medicines can be made into oral products, but they do not succeed just because the active ingredient was pressed into a pill. Developers may add coatings, enzyme blockers or absorption enhancers, then measure how much intact drug reaches the blood. The finished formulation is the tested product.

MOTS-c has no comparable published oral formulation or human absorption study. An enteric coating, which delays release until a pill reaches the intestine, would address stomach acid but would not automatically solve enzyme breakdown or passage through the gut wall. Words such as "liposomal" or "sublingual" are descriptions, not proof of delivery.

SS-31 is sometimes grouped with MOTS-c because both are studied around mitochondria. It is a different peptide with a different evidence base, and it does not validate an oral MOTS-c product.

What a MOTS-c supplement may really mean

The wrinkle is that MOTS-c is not foreign to the body. Human cells make it from a short reading frame in mitochondrial DNA. That fact gives sellers room to use phrases such as "MOTS-c support" or "MOTS-c booster" even when a capsule does not contain intact MOTS-c.

A support claim is not the same as delivery. The 2021 cycling experiment found that body-made MOTS-c rose in muscle and circulation after exercise in ten men. It did not test a supplement, and it did not show that swallowing amino acids, herbs or vitamins increases MOTS-c. Measuring a natural signal after exercise also does not prove that raising that signal would produce a health outcome.

The ingredient panel is therefore more useful than the name on the front. If it lists nutrients or plant extracts rather than MOTS-c, the product is a supplement built around a theory of support. It should not borrow results from studies in which researchers injected the intact peptide.

What changed in the 2026 FDA review

As of September 9, 2026, the day this article was written, an FDA staff briefing prepared for the July 23 Pharmacy Compounding Advisory Committee meeting said the agency had not identified publicly available human exposure data for MOTS-c by any route. It also said the evidence it reviewed was limited to cell and rodent models and proposed that MOTS-c free base and acetate not be added to the 503A Bulks List, the list FDA considers for traditional pharmacy compounding. That was a staff proposal in an advisory process, not a finding that an oral product works or a final rule about an individual patient.

MOTS-c has never been an FDA-approved product, and compounded MOTS-c is not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and doctor. The regulatory review does not settle every question about the peptide, but it makes the tablet question simple: there was no human route data to support an oral claim.

What the prescription route changes

Promise's MOTS-c product page lists a subcutaneous injectable vial, meaning it is placed under the skin, not a tablet. That does not turn early evidence into settled science. It does make the route, concentration, pharmacy and prescriber identifiable instead of leaving them behind a supplement label.

For a bottle advertised as MOTS-c pills or capsules, three distinctions matter: whether the ingredient is intact MOTS-c or a support blend, whether human absorption was measured for that exact formula, and whether the cited study used the same molecule and route. If any of those changes, the study is no longer direct evidence for the product in hand.

At Promise, a licensed provider reviews every request and prescribes or declines based on medical eligibility; not everyone qualifies. That review is also where route, monitoring and alternatives belong.